Clinical analysis of 43 cases with multiple myeloma surviving more than 5 years

Objective To analysis the relationship of clinical characteristics and prognosis of multiple myeloma (MM) patients surviving more than 5 years. Methods The clinical features, laboratory parameters and treatment programs of 43 cases diagnosed MM from September 2005 to September 2009 were collected to analyze the influence factors related to survival. Results 43 patients included 23 male cases, 20 female cases, with a median age of 59 years old (38-76 years old), and the median survival time was 80 months (60-124 months). Different ISS stage corresponded to different median survival phase, phase Ⅰ 120 months, phase Ⅱ 93 months, phase Ⅲ 80 months. The 43 patients had received the median of 25 cycles (15-46 cycles) of chemotherapy, all of them had received chemotherapy of bortezomib. The relapsed MM patients had received chemotherapy with bortezomib mainly, DECP, lenalidomide, arsenic trioxide and pcgylated liposomal doxorubicin. Conclusions Besides tumor burden, host factors and tumor biology, the prognosis of MM correlates with the treatment modality and response to therapy. The new target drugs such as bortezomib and lenalidomide have good curative effect on either newly diagnosed or relapsed and refractory MM. Key words: Multiple myeloma; Long survival; Prognosis